ClinicalTrials.gg

Program

trastuzumab botidotin

Its studies are mostly in Breast Neoplasms · Salivary Gland Neoplasms, led by 2 companies.

Furthest: phase 3, since Apr 26, 20254 company-led studies, 2 open or runningNext primary completion: Nov 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Kelun Pharmaceutical32 open or runningphase 3since Apr 26, 2025Mar 7, 2022Nov 30, 2026phase 3 · NCT06968585
Klus Pharma10 open or runningphase 2since Jul 6, 2018Jul 6, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 6, 2018First study: phase 2 study in Salivary Gland NeoplasmsNew to Klus PharmaKlus Pharma · NCT03602079 · 49 enrolled · United States
  2. Mar 7, 2022Sichuan Kelun Pharmaceutical’s first study: phase 1 study in Breast NeoplasmsNew to Sichuan Kelun PharmaceuticalSichuan Kelun Pharmaceutical · NCT05311397 · 129 enrolled · China
  3. Apr 26, 2025Phase 3 study in HER2-positive Breast CancerSichuan Kelun Pharmaceutical · NCT06968585 · 365 enrolled · China
  4. Dec 3, 2025Phase 2 study in Her 2 Positive Breast CancerSichuan Kelun Pharmaceutical · NCT07299825 · 40 planned · China

Ahead

  1. Nov 30, 2026Primary completion: phase 3 study in HER2-positive Breast CancerSichuan Kelun Pharmaceutical · NCT06968585
  2. Sep 20, 2027Primary completion: phase 2 study in Her 2 Positive Breast CancerSichuan Kelun Pharmaceutical · NCT07299825

TargetBeta

ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), ”NCIt, by rule
“Receptor tyrosine-protein kinase erbB-2 binding agent”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07299825Her 2 Positive Breast Cancer · China2RecruitingSichuan Kelun PharmaceuticalSep 20, 202740
NCT06968585HER2-positive Breast Cancer · China3Active, not recruitingSichuan Kelun PharmaceuticalNov 30, 2026365
NCT05311397Breast Neoplasms · China1CompletedSichuan Kelun PharmaceuticalApr 9, 2026129
NCT03602079Salivary Gland Neoplasms · United States2CompletedKlus PharmaJan 12, 202249

How it is read

Names in the registry

  • “A166”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.